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Mycosporine-like amino acids (MAAs) are UVR-absorbing metabolites typically produced by cyanobac-
teria and marine algae, but their properties are not limited to direct sun screening protection. Herein, we
examine the antioxidant activities of porphyra-334 and shinorine and demonstrate that these MAAs are
prospective activators of the cytoprotective Keap1-Nrf2 pathway. The ability of porphyra-334 and shi-
norine to bind with Keap1 was determined using ﬂuorescence polarization (FP) and thermal shift assays
to detect Keap1 receptor antagonism. Concomitantly, the ability of porphyra-334 and shinorine to
dissociate Nrf2 from Keap1 was conﬁrmed also by measurement of increased mRNA expression of Nrf2
targeted genes encoding oxidative stress defense proteins in primary skin ﬁbroblasts prior and post UVR
exposure. Surprisingly, enhanced transcriptional regulation was only promoted by MAAs in cells after
exposure to UVR-induced oxidative stress. Furthermore, the in-vitro antioxidant activities of porphyra-
334 and shinorine determined by the DPPH free-radical quenching assay were low in comparison to
ascorbic acid. However, their antioxidant capacity determined by the ORAC assay to quench free radicals
via hydrogen atom transfer is substantial. Hence, the dual nature of MAAs to provide antioxidant pro-
tection may offer a prospective chemotherapeutic strategy to prevent or retard the progression of
multiple degenerative disorders of ageing.
Crown Copyright © 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Kelch-like ECH-associated protein 1 (Keap1) is an actin
bound homodimer that functions as a primary sensor of intracel-
lular reduction-oxidation (redox) state regulation by controlling
the activity of the master transcription nuclear factor erythroid
2erelated factor 2 protein (Nrf2), which regulates the transcription
of a large number of genes under control of the cis-acting enhancer
termed the antioxidant response element (ARE) [1,2]. The human
Keap1monomer is a 69.7 kDa protein composed of 625 amino acids
that is divided into ﬁve distinct domains (Fig. 1). The Kelch-repeat
domain consists of six repeating motifs (KR1eKR6) that form aaceutical Sciences, Faculty of
Room 3.10 Franklin-Wilkins
ed Kingdom
ntal work.
vier B.V. This is an open access artisix-bladed b-propeller structure at which Keap1 binds to the Neh2
domain of Nrf2 [3]. Under basal conditions, Nrf2 is targeted for
ubiquitination and rapid 26S proteasomal degradation by Keap1
BTB domain bound Cullin3-Rbx1 E3 ubiquitin ligase (CRLKeap1)
[4e6]. This turnover of Nrf2 prevents unnecessary expression of
genes under Nrf2 transcriptional regulation [4]. During conditions
of oxidative stress, the ubiquitination and degradation of Nrf2 by
CRLKeap1 is disrupted by Nrf2-Keap1 dissociation. Two separate
models have been proposed for this dissociation: the “conforma-
tion cycling model” [5] and the “hinge and latch model” [6]. In the
conformation cycling model, it is proposed that, in the presence of
cellular oxidants and exogenous electrophiles, covalent modiﬁca-
tion of Cys151 in the BTB domain of Keap1 causes conformational
changes that prevent ubiquitination of Nrf2 by the CRLKeap1 protein
complex [6,7]. In the hinge and latch model, the Nrf2-Keap1
interaction is mediated by a high-afﬁnity ETGE motif in the Neh2
domain of Nrf2, which functions as a “hinge” by stabilising Nrf2
binding to the Kelch domain in the Keap1 dimer. A low-afﬁnity DLGcle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. Illustration of the Kelch-like ECH-associated protein 1 (Keap1). The Broad-complex, Tramtrack and Bric-a-Brac (BTB) domain, coloured green, is responsible for the
formation of the Keap1 dimer and for Cul3 binding; the Kelch-repeat (KR) domain, forms a six-bladed b-propeller structure with DLG and ETGE motifs that bind with the Neh2
domain of Nrf2 [6,10,13]. The Intervening (IVR) domain is comprised of amino acid residues between BTB and Kelch repeats. Cysteine residues that function as redox sensors are
denoted in the above illustration.
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or unlocking the binding position of Nrf2, depending on the redox
state of the cell. Under basal conditions, the DLG motif locks the
Neh2 domain in the correct position to enable ubiquitination of
Nrf2 [8,9]. However, the IVR domain of Keap1 is cysteine rich and
these residues are sensitive to oxidation [10e12]. During conditions
of oxidative stress, these cysteine residues become oxidized and
although the Nrf2 “latch” remains in a closed position with Nrf2
still bound to Keap1 through both its ETGE and DLG motifs, there is
a conformational change in Keap1 such that Nrf2 is no longer
correctly aligned with the CRLKeap1 complex and Nrf2 ubiquitina-
tion is thus disrupted [7]. As a consequence, Nrf2 is spared degra-
dation at the proteosome, and newly translated Nrf2 proteins
accumulate in the cell. Free Nrf2 then translocates to the nucleus
where it forms a complex with small Maf proteins and interacts
with the promoter region of the ARE to initiate the transcription of
genes encoding a vast arsenal of proteins that protect against toxic
contamination and regulate metabolic redox homeostasis [4,6,11].
Since oxidative stress has been implicated in numerous human
diseases, the Keap1eNrf2 protein-protein interaction (PPI) has
become an important target for the potential development of
therapeutic and chemopreventive agents [9]. Numerous com-
pounds have been examined for their ability to induce Nrf2-
dependent gene expression, including those of natural origin
(e.g., curcumin, sulforaphane) and others that are synthetic (e.g.,
bardoxolone methyl, oltipraz). Most of these Nrf2 activators are
electrophiles that covalently modify the sulfhydryl groups of Keap1
cysteine residues disrupting the ubiquitination and subsequent
degradation of Nrf2 [13]. These electrophilic inhibitors lack selec-
tivity and thus increase the risk of “off-target” toxic effects due to
indiscriminate reactions with cysteine residues of other cellular
proteins. Accordingly, the discovery of direct, non-reactive, small
molecule inhibitors of the Keap1eNrf2 PPI appears to be the most
promising strategy for Nrf2 activation to decrease the possibility of
“off-target” toxic effects [14,15].
Mycosporine-like amino acids (MAAs) are small secondary
metabolites commonly produced by marine algae and seaweeds
that reside in shallow-water environments and are typically
exposed to high levels of solar UVR (~295e400 nm) [16]. MAAs are
found also in the tissues of some marine vertebrates and in-
vertebrates, such as ﬁsh and krill, that occur by dietary accumula-
tion from themarine food-chain [17,18]. MAAs absorb UVR typically
between 310 and 340 nm, enabling MAAs to protect cells from solar
UVR-induced damage. Yet, MAAs are multifunctional metabolites
that protect also against free-radical damage and boost cellular
tolerance to desiccation, hyper-salinity and heat stress [16,19];
there are more than 20 known MAAs in this class of natural me-
tabolites (Fig. 2).
Previously, utilising protein modelling and virtual screening
methods, we had predicted the potential for Nrf2 activation by
competitive inhibition of its binding to Keap1, speciﬁcally by
certain UVR-protective MAAs [20]. Here we provide in vitro
empirical evidence to conﬁrm our in silico predictions thatporphyra-334 (the principal MAA of Porphyra yezoensis e Japanese
seaweed “nori”, Fig. 2c) and shinorine (from Gloiopeltis furcata e
Japanese seaweed “fukuro-funori”, Fig. 2b) may exert a cytopro-
tective function by speciﬁc, non-reactive binding to the Kelch-
repeat domain of Keap1. Additionally, these MAAs are shown to
have intrinsic antioxidant activity by quenching free oxygen radi-
cals through hydrogen atom transfer.
2. Materials & methods
2.1. Materials
All chemicals were purchased from commercial suppliers and
used without further puriﬁcation.
Ascorbic acid, tBHQ, caffeic acid and DMSO were purchased
from Sigma-Aldrich (Gillingham, Dorset, UK). Curcumin, DPPH,
quercetin, and EGCG were purchased from Insight Biotechnology
Ltd (Wembley, Middlesex, UK). Chlorogenic acid, trans-resveratrol
and sulforaphane were purchased from Cambridge Bioscience Ltd
(Cambridge, UK). Puriﬁed MAA compounds porphyra-334 and
shinorine were kind gifts from Prof Kazuo Yabe [21,22]. The pep-
tides FITC-(bAla)-DEETGEF-OH and Ac-DEETGEF-OH were syn-
thesised using Fmoc solid phase peptide synthesis as described
previously [23].
2.2. Fluorescence polarization (FP) assay
The FP assay was carried out as previously described [23].
Brieﬂy, a solution of ﬂuorescent peptide (FITC-(bAla)-DEETGEF-OH,
1 nM) and Keap1 Kelch domain (200 nM) in DPBS, pH 7.4 were
mixed in an untreated black 96 well plate (Corning) with varying
concentrations of test compounds up to 100 mM (ﬁnal DMSO con-
centration 11%, ﬁnal volume 100 mL) and incubated for 1 h at room
temperature in the dark. FP was measured using a PerkinElmer
EnVision™ Multilabel Plate Reader. All measurements were recor-
ded in triplicate. The normalised data were ﬁtted to a standard
dose-response equation by non-linear regression using Origin Pro
software (OriginLab) to determine IC50 values.
2.3. Thermal shift assay
The thermal shift assay was carried out as previously described
[24]. Brieﬂy, a solution of the detection dye SYPRO® orange (5X) and
Keap1 Kelch domain protein (5 mM) in DPBS, pH 7.4 were mixed in a
MicroAmp® Optical 96-well reaction plate (ThermoFisher) with
varying concentrations of test compounds up to 100 mM (ﬁnal
DMSO concentration 10%, ﬁnal volume 40 mL). The plate was sealed
using an optical adhesive cover and wrapped with aluminium foil
to protect the dye from light. The plate was then transferred to a
plate centrifuge and spun brieﬂy (200g, 1 min, at room temper-
ature) to remove any air bubbles and to collect the reaction mixture
at the bottom of the wells. The plate was incubated for 1 h at room
temperature and then placed into an Applied Biosystems 7500
Fig. 2. Structures and biophysical characteristics of MAAs tested in this study or of relevance for discussion in the text. Figure shows chemical structures of the mycosporine-
like amino acids, palythine, shinorine, porphyra-334 and mycosporine-glycine. The molecular formula, molecular mass, maximum wavelength of absorbance and absorbance
coefﬁcients are given for each MAA.
R. Gacesa et al. / Biochimie 154 (2018) 35e44 37Real-Time PCR machine and heated using a standard protein
melting protocol [25]. The ﬂuorescence intensity was recorded
with excitation at 465 nm and emissionmeasured at 580 nm during
a temperature scan from 25 C to 95 Cwith a temperature ramping
rate of 1 C/min. All measurements were performed in triplicate.
The raw data were exported to MS Excel and analysis was per-
formed using a custom script provided by Structural Genomics
Consortium, University of Oxford. The temperature range over
which protein unfolding occurred was established at temperatures
below the maximum ﬂuorescence intensity. The processed data
were ﬁtted to the Boltzmann equation by non-linear regression
analysis using Origin Pro software.Fig. 3. Measurement of speciﬁc, non-reactive binding of MAAs to the Kelch-repeat
domain of Keap1. Ligand-receptor binding was measured using a ﬂuorescence po-
larization assay in comparison to a high afﬁnity, labelled synthetic peptide. The MAAs
porphyra-334 and shinorine gave moderate IC50 values of ~100 mM, whereas no sig-
niﬁcant interactions were detected between the Keap1 Kelch-repeat domain and any
of the eight selected antioxidants or known electrophilic Nrf2 activator sulforaphane.
The ﬁgure shows results for 100 mM concentration of MAAs and known antioxidants.
Error bars represent one standard deviation of the mean, based on 3 experimental
replicates, and statistically signiﬁcant results (based on p-value of two sided t-
test 0.05 adjusted for multiple testing based on Bonferroni correction) are marked
with an asterisk.2.4. Transcription of Nrf2 targeted genes
Measurements of Nrf2 protein were made with the primary
dermal ﬁbroblast cell line 1BR (a gift from Dr Mieran Sethi, King's
College London). Cells were grown [26] to ~ 70% conﬂuency in 12-
well plates containing DMEM (Invitrogen, UK) supplemented
with 10% (v/v) FCS (Sigma-Aldrich, UK) and 1% (w/v) each of
penicillin and streptomycin (Invitrogen, UK). Cells were irradiated
with 100 J/cm2 of UVA1 (340e400 nm) radiation using a Loctite
LED ﬂood array system with peak output at 385 nm and FWHM of
7 nm (Loctite, Henkel Ltd, UK). The spectrumwas measured using a
DM120BC double monochromator spectroradiometer (Bentham
Instruments, Reading, UK) using an integration sphere, calibrated
by the Centre for Radiation, Chemical and Environmental Hazards
(CRCE), Public Health England against a UK national standard.
Irradiance of the sources was routinely measured with a Loctite
UVA/Vis radiometer (Loctite, Henkel Ltd, UK). Cells were then
treated by the addition to the medium of 100 mM of either
porphyra-334 or shinorine, or 10 mM sulforophrane for 24 h. Sul-
forophane concentration was determined based on maximum
concentration found not to induce signiﬁcant toxicity to the cell line
(viability> 75%). All treatments were repeated in triplicate. Total
RNAwas isolated from the cells using the mirVana miRNA isolation
kit with phenol (Life Technologies, USA) on ice according to the
manufacturer's instructions. Synthesis of cDNA was carried out
using a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems by Life Technologies, USA), again following the manu-
facturer's instructions. Quantitative RT-PCR of the following geneswas performed in 96-well plates using TaqMan Gene Expression
Assays (Thermoscientiﬁc, Waltham, USA) according to the manu-
facturer's instructions: NFE2L2 (encoding human Nrf2), Keap1, GCLC
(glutamate-cysteine ligase), GCLM (glutamate-cysteine ligase
modiﬁer subunit), HMOX-1 (heme oxygenase 1), and MMP-1 (ma-
trix metalloproteinase 1). The ampliﬁed products were analysed
using an ABI prism 7900 HT sequence detection system (Applied
Biosystems). The housekeeping gene GAPDH (glyceraldehyde 3-
phosphate dehydrogenase) was labelled using 4,7,20-trichloro-70-
phenyl-6-carboxyﬂuorescein as a positive control. The probes for
the genes of interest were labelled with 6-carboxyﬂuorescein (Life
Technologies, USA). Transcription of NFE2L2, Keap1, GCLC, GCLM,
R. Gacesa et al. / Biochimie 154 (2018) 35e4438
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Data analysis was performed using the DDCycles threshold (Ct)
method [25]. The DDCt value was determined using the formula:
DDCt ¼ (CtGOI -CtHK), with CtGOI being the average Ct value for the
gene of interest and CtHK the average Ct value of GAPDH. These data
were expressed as mRNA expression fold changes, relative to the
calibration sample. Assuming a doubling of material during each
PCR cycle, the relative quantiﬁcation (RQ) was estimated according
to the formula: (RQ)¼ 2DDCt.2.5. DPPH radical scavenging activity assay
The percentage of antioxidant scavenging activity for each MAA
was determined as follows, each MAA (62.5 mM, 117.7 mM and
210.5 mM concentrations) and an ascorbic acid positive control
(3.9 mM, 7.8 mM, 15.6 mM, 31.3 mM, 62.5 mM and 312.5 mM concen-
trations) were prepared in DMSO. For each sample, the reaction
mixture consisted of 0.1mL of the test sample and 1.5mL of 70 mM
DPPH in methanol. The colour change from violet to yellow, when
DPPH is reduced upon reaction with an antioxidant, was recorded
at 515 nm using a UV/VIS spectrophotometer (model 7315, Jenway
Ltd., Stone, Staffordshire, UK) after 30min at room temperature,
with reaction mixtures shielded from light. The mixture of DMSO
(0.1mL) and DPPH (1.5mL) served as the reaction blank. The per-
centage of DPPH radical scavenging activity was calculated as: %
scavenging activity¼ 100 x (Ablank e Asample)/Ablank. The DPPH scav-
enging activity was proportional to the MAA concentration (for
levels examined), and the 515 nm absorbance of the fully reduced
DPPH was set to zero. Experiments were performed in technical
triplicates with three replicates, and % scavenging activities were
plotted as the mean of the 9 triplicate/replicate values against test
sample concentrations (mM). IC50 values were estimated from linear
regression of the data.2.6. ORAC antioxidant assay
The oxygen radical absorbance capacity for each MAA was car-
ried out using the ORAC Antioxidant Assay Kit (Zenbio, North Car-
olina, USA) according to manufacturer's instructions. Trolox
standards were prepared in the assay buffer (0e100 mM) along with
serial dilutions of each MAA (500-0 mM) and an ascorbic acid pos-
itive control (0e100 mM). 150 ml of the ﬂuorescein working solution
was added to central wells of a 96 well plate, with 25 ml of each of
the standards or MAA in duplicate, and the plate incubated at 37 C
for at least 15min. The 2,20-azobis(2-amidinopropane) dihydro-
chloride [AAPH; sold as 2,20-azobis(2-methylpropanimidamine)
dihydrochloride] working solutionwas added to eachwell (25 ml) to
initiate the reaction. Fluorescence was measured in a preheated
incubation chamber (37 C) using a Spectra Max 384 Plus spec-
trophotometer with excitation/emission¼ 485/530 nm immedi-
ately (t¼ 0) and then every minute for 30min. Standard curves
were generated for each compound and the area under the curve
calculated. Each MAA tested was expressed as a Trolox equivalent
concentration.Fig. 4. Transcription of Nrf2 targeted genes. Differential expression of genes associated wit
changes in transcription were measured±UVA1 irradiation (100 J/cm2) and post exposure
were added to the growth medium. There was no change in the expression of NFE2L2 or Keap
for all other genes tested (p< 0.05). Treatment with the MAAs alone led to no signiﬁcant chan
exposure there was a signiﬁcant increase in GCLC and GCLM expression over that of the cel
HMOX-1, however the data was not signiﬁcant. Expression of MMP-1 was signiﬁcantly incre
exposure treatment with all test compounds (p< 0.05). There was no change in MMP-1 exp
value ± SEM (n¼ 4).3. Results
3.1. MAAs Porphyra-334 and shinorine compete with Keap1-Nrf2
interaction in vitro
The MAAs porphyra-334 and shinorine together with eight
selected antioxidants (ascorbic acid, tBHQ, caffeic acid, chlorogenic
acid, curcumin, quercetin, EGCG, trans-resveratrol) plus the known
electrophilic Nrf2 activator sulforaphane were evaluated for their
interaction with the Kelch-repeat domain of the Keap1 protein
using both in vitro FP and thermal shift assays. In the FP assay, the
test compounds competed with a ﬂuorescein labelled peptide
(FITC-[b-Ala]-DEETGEF-OH) based on the high afﬁnity ETGE motif
that binds Nrf2 to the Kelch-repeat domain (Fig. 3). The protein-
protein interaction of the FITC-[b-Ala]-DEETGEF-OH peptide had
a KD of 96 nM in the presence of the Kelch-repeat domain protein
and the unlabelled Ac-DEETGEF-OH peptide competed with this
interaction with an IC50 of 5.4 mM [23]. Both porphyra-334 and
shinorine gave nearly equivalent ligand-receptor estimated IC50
values of ~100 mM, requiring a much greater concentration in the
presence of excess Kelch-repeat domain protein than the binding of
the native peptide sequence [23]. In contrast, no signiﬁcant in-
teractions were detected between the eight known antioxidants or
sulforaphane and the Kelch-repeat domain protein.
The MAAs and eight selected antioxidants were then tested as
ligands of the Kelch-repeat domain protein using the thermal shift
(differential scanning ﬂuorimetry, DSF) assay. The assays involved
treatment of the Kelch-repeat domain protein with the test com-
pounds of interest, followed by heating of the samples to denature
the protein. Ligands that bind and stabilise the Kelch-repeat
domain protein result in higher denaturation (Tm) temperatures
for the complex compared to the free protein. An unlabelled version
of the peptide (Ac-DEETGEF-OH) used in the FP assay was used as
the positive control in the thermal shift assays against which
binding of the test compounds to the Kelch-repeat domain were
compared. When used at a 50 mM concentration, the Ac-DEETGEF-
OH peptide had a DTm relative to the unbound protein of
3.91± 0.04 C. Both porphyra-334 and shinorine also demonstrated
elevated DTm values to the Kelch-repeat domain protein, albeit
when used at 100 mM (porphyra-334 DTm¼ 0.93± 0.02 C, shi-
norine DTm¼ 0.64± 0.11 C). However, no signiﬁcant protein-
ligand interactions were detectable when the eight antioxidants
or the electrophilic Nrf2 activator sulforaphane were tested. The
thermal shift assays reﬂected the results of the FP assays for binding
of MAAs and test substrates to the Kelch-repeat domain protein of
Keap1.3.2. Porphyra-334 and shinorine induce Nrf2-regulated antioxidant
response in ﬁbroblasts
Porphyra-334 and shinorine, together with the known Nrf2
activator sulforaphane were added to primary human dermal
ﬁbroblast cells prior to and post UVA irradiation, with UVA dose of
100 J/cm2 which is equivalent to a single-day exposure to summer-
day sunlight [27]. Gene expression levels for Nrf2, Keap1 and for
Nrf2 targeted downstream genes glutamate-cysteine ligaseh Nrf2 activation: 4a. NFE2L2, 4b. Keap1, 4c. GCLC, 4d. GCLM, 4e. HMOX-1, 4f.MMP-1. Fold
incubation when porphyra-334 (100 mM), shinorine (100 mM) or sulforaphane (10 mM)
1 genes with any treatment. UVA1 treatment led to a signiﬁcant increase in expression
ge, however when cells were irradiated and incubated with MAAs or sulforaphane post
ls exposed to UVA1 radiation alone (p< 0.05). A similar relationship was observed for
ased following UVA1 exposure, however this was signiﬁcantly reduced following post
ression with any treatment without UV irradiation. Each column represents the mean
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unit (GCLM), heme oxygenase 1 (HMOX1) and matrix metal-
loproteinase 1 (MMP-1) were also measured 24 h after addition of
each test compound. The results showed no signiﬁcant changes in
Nrf2 (Fig. 4a) or Keap1 (Fig. 4b) gene expression levels, which was
expected for constitutively expressed genes. However, GCLC
(Fig. 4c) and GCLM (Fig. 4d) gene expression was signiﬁcantly
enhanced in the presence of MAAs and sulforaphane after UVA
exposure. Expression of these genes was also signiﬁcantly
increased in the absence of UVA-induced oxidative stress following
addition of sulforaphane, but not following the addition of any of
the MAAs without prior UVA treatment (Fig. 4c and d). HMOX1
gene expression had increased also in the presence of these test
compounds post irradiation, although this increase was not sta-
tistically signiﬁcant (Fig. 4e). There was a signiﬁcant increase in
MMP-1 gene expression following UVA irradiation, which was
signiﬁcantly reduced following addition of the MAAs and sulfo-
raphane (Fig. 4f). Again, MMP-1 gene expression was only
repressed in the presence of MAAs following induction of oxidative
stress, whereas gene expression could be signiﬁcantly reduced
upon exposure of ﬁbroblasts to sulforaphane without prior UVA
irradiation.3.3. Porphya-334 and shinorine are in-vitro antioxidants
Scavenging of the DPPH free radical is a common assay used to
assess the antioxidant activity of a compound. Ascorbic acid is a
well-known DPPH free-radical scavenger and is commonly used as
a positive control, which was used also for comparison in this study.
The IC50 value for ascorbic acid was 24.5± 1.1 mM in the methanol
reaction medium. The free radical scavenging activities of MAAs
were markedly lower compared to that of ascorbic acid. The IC50
values were: 185.2± 3.2 mM for porphyra-334 (equivalent to 13.23%
of the activity of ascorbic acid) and 399.0± 1.1 mM for shinorine
(equivalent to 6.14% of the activity of ascorbic acid).
Another method commonly used to assess antioxidant activity
is the ORAC assay, which is used to assess the hydrogen atom
transfer capacity of a test compound to suppress peroxyl radical
(ROO$) induced oxidative damagemeasured by the radical-induced
ﬂuorescence decay of ﬂuorescein. Trolox, a water-soluble vitamin E
analogue, was used as the standard against which other com-
pounds typically are compared, and ascorbic acid was used also asFig. 5. The oxygen radical absorbance capacity of MAAs. MAAs and reference con-
trols at increasing concentration were assessed for their ability to quench the [ROO$]
radical as a measure of antioxidant activity. All compounds demonstrated signiﬁcant
activity (trolox p¼ 0.0002; ascorbic acid p¼ 0.0015; porphyra-334 p< 0.0001; shi-
norine p¼ 0.0002; determined by linear regression analysis). Relative antioxidant
capacity compared to trolox was calculated (ascorbic acid¼ 130 ± 12%; porphyra-
334¼ 51± 7%; shinorine¼ 17± 7%). Each data point represents the mean value ± SEM
(n¼ 3).an additional control reference. Both MAAs demonstrated signiﬁ-
cant activity (Fig. 5) with porphyra-334 displaying an antioxidant
capacity equal to 51± 7% of equimolar Trolox and shinorine
showing 17± 7% of the Trolox capacity. Ascorbic acid showed
greater antioxidant capacity than did Trolox (equivalent to
130± 12% of Trolox) and that of our test MAAs. These controls are
shared with previously published work [26].
4. Discussion
Aerobic organisms are regularly challenged by various envi-
ronmental oxidants and toxic electrophiles that include free radi-
cals produced from exposure to UV, visible and IR radiation,
xenobiotic pollutants and endogenously generated, reactive by-
products of oxidative metabolism. As such, these organisms have
long evolved a robust detoxiﬁcation and redox signalling systems to
prevent cellular damage [4,9]. The transcription factor Nrf2, tar-
geting ARE upstream promoter sites of many protective genes, is
the principal regulator of mammalian cellular antioxidant defence
and P-450 cytochrome detoxiﬁcation proteins. While various
intrinsic pathways and signalling cascades have been identiﬁed
that contribute to the regulation of Nrf2 function [4,28], the key
role of the repressor Keap1 protein is ﬁrmly established since
disruption of Keap1-Nrf2 binding is sufﬁcient to increase nuclear
Nrf2 activity signiﬁcantly [29,30]. This is supported additionally by
siRNA knockdown of Keap1 mRNA [31] and Keap1-null ablation
[29], both of which massively enhance free cellular Nrf2 accumu-
lation. Furthermore, somatic mutations of Keap1, a characteristic of
certain cancer phenotypes [32,33], result in constitutive Nrf2 acti-
vation, as does the silencing of Keap1 expression by miRNAs
[34,35], or by epigenetic hyper-methylation of the Keap1 promoter
[36].
Human Keap1 contains six ROS/electrophile-sensing cysteine
residues (Cys151, Cys226, Cys273, Cys288, Cys434 and Cys613),
which are prone to oxidation and covalent modiﬁcation by elec-
trophiles. These changes do not prevent Keap1-Nrf2 binding, but
alter the basal-state “open” conformation, which prevents CRLKeap1
ubiquitination to release Keap1 upon Nrf2 degradation [7]. As a
result, free Keap1 is not regenerated, and newly synthesised Nrf2
accumulates to promote gene transcription. Electrophile activators
of Nrf2 and the majority of other known Nrf2 inducers, including
sulphoraphane used in this study, function by covalent targeting
critical Cys residues of Keap1 to activate Nrf2 transcription [4,37].
The compounds examined in this study, with the exception of the
Keap1-binding MAAs, are sometimes referred to as “indirect anti-
oxidants” or “Nrf2-activating antioxidants” and would not be ex-
pected to show appreciable activity in the FP, thermal shift, DPPH or
ORAC assays. These expectations were matched by our assay
results.
Non-electrophile activators of Nrf2, e.g. small-peptides [23,38]
and small-molecule Nrf2 activators [39,40], function by competi-
tive inhibition of Keap1-Nrf2 binding. These compounds hinder the
formation of the “closed” Keap1-Nrf2 conformation by binding to
the Keap1 b-propeller structure responsible for DLG and ETGE
binding.While less studied than electrophile-based Nrf2 activation,
targeting of the Keap1-Nrf2 binding site by competitive inhibitors
has potential to upregulate Nrf2 activity without the toxic danger of
indiscriminate “off-target” effects. These compounds and peptides
do not depend on covalent electrophile modiﬁcation of protein
cysteine residues and thus are not prone to indiscriminate reactions
with proteins of other cellular signalling networks [2]. In this study
we present empirical in vitro evidence for the MAAs porphyra-334
and shinorine to competitively interact with the Nrf2 binding site of
the human Keap1 protein, as previously anticipated from bio-
informatic, structure-based Kelch domain binding predictions [20].
R. Gacesa et al. / Biochimie 154 (2018) 35e44 41The ﬁrst study to examine the antioxidant properties of MAAs,
using the phosphatidylcholine peroxidation inhibition assay, found
that imino-MAAs (shinorine, porphyra-334, palythine, asterina-330
and palythinol) were oxidatively robust to AAPH-generated peroxyl
radicals, whereas the oxo-MAA mycosporine-glycine strongly
inhibited radical-initiated phosphatidylcholine autoxidation in a
concentration-dependent manner [41]. 4-Deoxygadusol, presumed
to be the immediate biochemical precursor of MAAs, was found
also to have strong antioxidant properties [42] as demonstrated by
voltamperogramic comparison of the electrochemical properties of
4-deoxygadusol, mycosporine-glycine and mycosporine-taurine
[16]. Numerous studies on the antioxidant properties of MAAs
followed thereafter and have been extensively reviewed [43].
Notably, the antioxidant capacities of porphyra-334 and shinorine,
together with other MAAs isolated from marine extracts (three
seaweeds and one lichen), were compared using the ABTS radical-
cation decolorization and superoxide-scavenging pyrogallol
autoxidation assays, which showed scarce activity in comparison to
mycosporine-glycine [44]. Yet, shinorine and porphyra-334 showed
modest antioxidant activity using the b-carotene/linoleate bleach-
ing assay [45]. Contrasting reports by Rastogi et al. attribute sig-
niﬁcant antioxidant activities of cyanobacterial extracts containing
a mixture of imino-MAAs, albeit the IC50 values of theseMAAswere
approximately 15e30% that of the antioxidant activity of ascorbic
acid as measured by DPPH-radical, ferric-reducing antioxidant
power (FRAP) and superoxide radical scavenging activity (SRSA)
assays [45,46]. We report also that puriﬁed shinorine and
porphyra-334 showed low antioxidant activity in the DPPH radical
assay [26] but exhibited signiﬁcant antioxidant activity using the
ORAC assay, which is a measure of the oxygen radical absorbance
capacity of a test substance. We recently demonstrated also using
the ORAC assay that palythine has signiﬁcant antioxidant activity
having an antioxidant capacity comparable to that of ascorbic acid
[26]. Our DPPH assay ﬁndings are consistent with established data
[43], whereas our ORAC assay results reveals that both pophyra-
334 and shinorine have signiﬁcant antioxidant capacity by
quenching oxygen radicals by hydrogen atom transfer, rather than
by reductive electron transfer [26].
Several recent publications describe the immunoregulatory and
anti-inﬂammatory properties of mycosporine-glycine, shinorine
and porphyra-334 [47e49]. Suh et al. [47] reported that treating the
human keratinocyte cell line HaCaT with mycosporine-glycine
resulted in a signiﬁcant decrease in UVR-induced, inﬂammatory
COX-2 mRNA levels, whereas all MAA treatments increased
expression levels of the UVR-suppressed, procollagen C proteinase
enhancer and elastin genes. Becker et al. [48] found that both shi-
norine and porphyra-334 induced nuclear factor NF-kB activity in
the NF-kB/AP-1 reporter myelomonocyte cell line THP-1-blue,
although NF-kB induction was greater with shinorine. Yet, while
shinorine marginally enhanced LPS-superinduced NF-kB activity,
porphyra-334 signiﬁcantly reduced the NF-kB response in LPS-
stimulated cells. Ryu et al. [49] had reported previously that
porphyra-334 had an inhibitory effect on the expression of NF-kB
dependent inﬂammatory genes, such as IL-6 and TNF-kB, in UVA-
irradiated skin ﬁbroblasts, but pertinent to this study is ﬁnding
that porphyra-334 can activate the Nrf2 signalling pathway in UVA-
irradiated cells. However, nuclear Nrf2 translocation by porphyra-
334 without concurrent ROS production by UVA exposure had
not been demonstrated [49]. Our gene expression results afforded
similar trends to these data [47e49], with enhanced expression of
Nrf2 targeted downstream genes following exposure to MAAs or
sulforaphane in cells pre-exposed to UVA-induced oxidative stress
(Fig. 4cee). Surprisingly, when cells were treated with MAAs but in
the absence of prior oxidative stress, there was no change in
expression levels of GCLC, GCLM or HMOX-1 genes, yet conversely,the expression levels of these genes were enhanced by treatment
with sulforaphane alone. This unexpected observation suggests
that MAAs are antagonists of Keap1-Nrf2 binding only after expo-
sure to cellular conditions of oxidative stress, whereas sulforaphane
induced Nrf2 activation regardless of the cellular redox state. Pre-
vious research has demonstrated that UVA irradiation is insufﬁ-
cient alone to heighten translocation of Nrf2 protein to the nucleus,
or to activate expression of Nrf2 targeted genes [50]. Over expres-
sion of Nrf2 targeted genes is known, however, to afford enhanced
UV-induced photo-protection as demonstrated in a variety of
different cell-lines [26,46,48] and a mouse model [51]. UVA irra-
diation of mammalian cells does enhance the expression of genes
regulated by transcription factors YAP and NF-kB [52,53], yet the
genes targeted by these transcription factors are distinct from those
regulated by Nrf2. Thus, UVA induced activation of YAP and NF-kB
cascades is unlikely to explain the over expression of GCLC, GCLM or
HMOX-1 demonstrated in this study, and also reported in the pre-
vious investigation by Ryu et al. [49]. It has been recognised that the
activity of Nrf2 can be regulated independently of Keap1 through
the NF-kB cascade [52e54] and by the activity of other UV-sensitive
proteins such as the small Rho GTPase, Rac1 [55,56]. We suggest
that UVA-activated kinases might weaken the interaction between
Keap1 and Nrf2, allowing porphyra-334 and shinorine to inhibit
Keap1-Nrf2 binding at concentrations insufﬁcient to interrupt
these interactions in cells not exposed to UVA. However, the mo-
lecular stress-signalling process of this activation is clearly yet
unknown and warrants future study, although we posit that
enhanced release of Nrf2 from Keap1 by MAAs conditional to UVR-
induced oxidative stress could be advantageous for future thera-
peutic development of these natural products. MMP-1 gene
expression is widely used as an acceptedmarker of oxidative stress-
induced photoageing of human skin [57]. When cells were treated
with either the test MAAs or sulforaphane post UVA exposure,
there was a signiﬁcant decrease in MMP-1 expression, clearly
demonstrating a protective effect (Fig. 4f). Again, transcriptional
regulation by MAAs was only observed in cells that had been prior
irradiated. These results lend support to our ﬁndings that MAAs are
prospective activators of the cytoprotective Keap1-Nrf2 pathway by
Keap1 receptor antagonism. Evidence of nuclear translocation of
Nrf2 must now be collected if the ability of porphyra-334 and
shinorine to dissociate Nrf2 from Keap1 is to be unambiguously
conﬁrmed.
Sustained oxidative damage is a primary cause of inﬂammation,
ageing and contributes to numerous age-related chronic diseases
including cancer, diabetes, atherosclerosis, hypertension, stroke
and dementia [58e60]. Accordingly, Nrf2 activation has been
shown in mouse models to mitigate the progression of various
neurodegenerative disorders: Alzheimer's disease, Parkinson's
disease, amyotrophic lateral sclerosis, Huntington's disease, and
multiple sclerosis [61]. It is widely accepted that oxidative stress
increases with ageing [62] due, in part, to a corresponding loss of
cellular Nrf2 activity [63]. Suppressed Nrf2 activity is considered a
driver of premature ageing [64], and constitutive levels of Nrf2-
signalling is claimed to be a key determinant of health span and
species longevity [65e67]. Contrary to these beneﬁts, and although
low levels of Nrf2 activity predispose cells to chemical carcino-
genesis, loss of Keap1 function and elevated Nrf2 levels have been
detected in various cancer tumours, which enhances cell prolifer-
ation and resistance to chemotherapeutic drugs [68e70], a phe-
nomenon dubbed the “dark side of Nrf2” [71] and the “double-edge
sword of Nrf2” [72]. Furthermore, extensive mapping of somatic
mutations in human cancer tumours has identiﬁed a high number
of mutations clustered in the Neh2 domain of Nrf2 within the
proximity of the ETGE and DLG motifs [73,74]. Where Nrf2 is
constitutively hyper-activated in certain cancer phenotypes, such
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clinical prognosis [32,75,76], while cancers with low Nrf2 activity
appear less resistant to chemotherapy and are thus more success-
fully treated [77]. Cancers can be classiﬁed depending on Nrf2 ac-
tivity levels, and clinical determination to inhibit Nrf2 activity has
potential to aid in cancer treatment [78,79]. The binding afﬁnity of
porphyra-334 and shinorine to Keap1 (~100 mM) were weak in
comparison to reported Keap1-Nrf2 PPI activators. For example,
Jiang et al. [15], demonstrated that a synthetic compound could
effectively disrupt Keap1-Nrf2 PPI with an EC50 of 28.6 nM in the
FP assay. Jain et al. [80] similarly reported that the ethyl ester of a
synthetic naphthalene-based non-electrophilic compound could
also disrupt Keap1-Nrf2 PPI in the nanomolar range, with an IC50 of
61 nM in an FP assay. Given consideration that excessive activation
of Nrf2 regulated genes may be deleterious, we contend that sys-
temic “soft” Nrf2 activation by the natural products shinorine and
porphyra-334, having moderate but speciﬁc afﬁnity for binding to
Keap1 in speciﬁc response to cellular oxidative stress, may be
highly desirable [81].
5. Conclusion
We demonstrate that pophyra-334 and shinorine, sourced from
commercial food-grade seaweeds, are unique natural products that
can provide both a direct antioxidant defence and stimulate
enhanced cytoprotection by activating the molecular Keap1-Nrf2-
ARE pathway. Commercial development of MAAs for use in
topical sunscreens has been rekindled with evidence now that
certain synthetic organic ﬁlters can damage the environment and
possibly be harmful to human health [19,26]. Likewise, therapeutic
beneﬁts in human degenerative diseases of ageing also wait vali-
dation by testing in appropriate disease models.
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